Cover Image
市場調查報告書

Synthon BV的產品平台分析

Synthon BV - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 306085
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Synthon BV的產品平台分析 Synthon BV - Product Pipeline Review - 2014
出版日期: 2014年06月15日 內容資訊: 英文 29 Pages
簡介

本報告提供Synthon BV的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Synthon BV的基本資料

Synthon BV概要

  • 主要資訊
  • 企業資料

Synthon BV:R&D概要

  • 主要的治療範圍

Synthon BV:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Synthon BV:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Synthon BV:藥物簡介

  • Secretory IgA
  • SYD-985
  • Biosimilar-2
  • Immunotherapeutic IgG
  • 腫瘤的單株抗體

Synthon BV:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Synthon BV:最近的開發平台趨勢

Synthon BV:暫停中的計劃

Synthon BV:企業發表

Synthon BV:總公司和子公司的所地

附錄

目錄
Product Code: GMDHC04998CDB

Global Markets Direct's, 'Synthon BV - Product Pipeline Review - 2014', provides an overview of the Synthon BV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Synthon BV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Synthon BV including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Synthon BV's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Synthon BV's pipeline products

Reasons to buy

  • Evaluate Synthon BV's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Synthon BV in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Synthon BV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Synthon BV and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Synthon BV
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Synthon BV and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Synthon BV Snapshot
    • Synthon BV Overview
    • Key Information
    • Key Facts
  • Synthon BV - Research and Development Overview
    • Key Therapeutic Areas
  • Synthon BV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Synthon BV - Pipeline Products Glance
    • Synthon BV - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Synthon BV - Drug Profiles
    • Secretory IgA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SYD-985
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Immunotherapeutic IgG
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugated 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugated 3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugated 4 For Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Synthon BV - Pipeline Analysis
    • Synthon BV - Pipeline Products by Target
    • Synthon BV - Pipeline Products by Molecule Type
    • Synthon BV - Pipeline Products by Mechanism of Action
  • Synthon BV - Recent Pipeline Updates
  • Synthon BV - Dormant Projects
  • Synthon BV - Company Statement
  • Synthon BV - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Synthon BV, Key Information
  • Synthon BV, Key Facts
  • Synthon BV - Pipeline by Indication, 2014
  • Synthon BV - Pipeline by Stage of Development, 2014
  • Synthon BV - Monotherapy Products in Pipeline, 2014
  • Synthon BV - Out-Licensed Products in Pipeline, 2014
  • Synthon BV - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Synthon BV - Preclinical, 2014
  • Synthon BV - Discovery, 2014
  • Synthon BV - Pipeline by Target, 2014
  • Synthon BV - Pipeline by Molecule Type, 2014
  • Synthon BV - Pipeline Products by Mechanism of Action, 2014
  • Synthon BV - Recent Pipeline Updates, 2014
  • Synthon BV - Dormant Developmental Projects,2014
  • Synthon BV, Subsidiaries

List of Figures

  • Synthon BV - Pipeline by Top 10 Indication, 2014
  • Synthon BV - Pipeline by Stage of Development, 2014
  • Synthon BV - Monotherapy Products in Pipeline, 2014
  • Synthon BV - Pipeline by Top 10 Molecule Type, 2014
Back to Top